In contrast to lung adenocarcinomas, which often have EGFR kinase domain mutations that confer resistance to EGFR-TKI treatment, EGFR mutations are lacking or diverse in different clinical breast cancer datasets [4]. Here, EGFR is linked to breast carcinoma.